• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

One-time telephone interventions have little effect on drug abuse

byJohn PrendergassandBrittany Hasty, MD
August 5, 2014
in Chronic Disease, Public Health
Reading Time: 3 mins read
One-time telephone interventions have little effect on drug abuse
Share on FacebookShare on TwitterShare on LinkedIn

1. No significant difference from baseline drug use was observed in patients who received a thirty minute telephone session of motivational interviewing. 

2. Individuals with a high severity of drug abuse were more likely to enter specialist drug treatment programs and reduce their use of the emergency department.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: In our country, alcohol and drug abuse affects individuals of all socioeconomic classes, cultures, and ages. The physical effects of drug abuse are well known and include liver failure, kidney disease, encephalopathy, and cardiomyopathy, among other systemic conditions. The public health and societal implications of drug abuse, however, are less advertised. These include increased mortality, crime, lost productivity in the workplace, and ever increasing medical care costs. Such consequences of drug abuse affect not only the abuser but the country as a whole.

With this in mind, this study set out to determine if thirty minute telephone interviews concerning an individual’s drug abuse may have an affect of their frequency of use. Patients were recruited from waiting rooms and primary care clinics. Secondary outcomes included inpatient hospitalizations, arrest records, and death rates. Ultimately, no significant decrease in drug use nor secondary outcomes was observed at 3 months after the intervention. A major weakness of the study was the heterogeneity of drug use among its participants, including marijuana, opiates, and stimulants. Another weakness was a high rate of mental illness in the study population. Combined, these aspects of the study greatly hinder reproducibility. While the intervention did not prove workable, it did demonstrate how much more work is needed to affect drug abuse on a grand scale. Future studies should focus on examining the effect of more targeted, aggressive, interventions on those with a high severity of abuse.

Click to read the study, published today in JAMA

RELATED REPORTS

Samsung BioLogics lands $1.3 billion U.S. contract amid tariff uncertainty

Corstasis’ Enbumyst nasal spray approved for edema

Relevant Reading: Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse

In-Depth [randomized controlled trial]: This 2-group randomized clinical trial consisted of 846 patients recruited between April 2009 and September 2012 from the waiting rooms of hospitals and primary care clinics in Washington. 423 (97%) patients received a brief intervention and 203 (47%) received a booster call. Mean days used of the most common problem drug at baseline were 14.40 (SD,11.29) (brief intervention) and 13.25 (SD, 10.69) (enhanced care as usual). At 3 months postintervention, brief intervention mean was 11.87 (SD, 12.13) and enhances care as usual mean was 9.84 (SD, 10.64). There was no significant difference in either of these groups from baseline (difference in differences, β = 0.89 [95% CI, −0.49 to 2.26]). There was also no significant difference in secondary outcomes from baseline.

Image: CC/Wiki

More from this author: Reducing surgical complications may increase costs,Protected sleep periods improve intern alertness and sleep duration,ADHD medication decreases rates of criminality in ADHD patients,Low dose aspirin shows net clinical benefit in patients with first unprovoked venous thromboembolism, Rare TREM-2 mutation implicated in Alzheimer’s Disease

 ©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: drugs
Previous Post

Immune-modulating enteral nutrition does not reduce infections in the ICU

Next Post

Early alteplase treatment leads to better stroke outcomes regardless of age or stroke severity

RelatedReports

Adalimumab use results in high clinical response rate in hidradenitis suppurativa
All Specialties

Samsung BioLogics lands $1.3 billion U.S. contract amid tariff uncertainty

September 23, 2025
Variation noted across pre- and post-marketing studies for FDA approved devices
Pharma

Corstasis’ Enbumyst nasal spray approved for edema

September 18, 2025
2 Minute Medicine AI Roundup editorial illustration
AI Roundup

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

September 25, 2025
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Pharma

Drugmakers Increase Prices on Over 250 Medications

May 21, 2025
Next Post
No obesity paradox found between BMI, stroke, and death

Early alteplase treatment leads to better stroke outcomes regardless of age or stroke severity

Pro-vaccine messages not associated with increased vaccination intent

BCG vaccine protective against active tuberculosis in children

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Optogenetic therapy may partially restore vision in retinitis pigmentosa
  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
  • Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.